{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:49:30Z","timestamp":1792050570422,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.02.003","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:30:46Z","timestamp":1707741046000},"page":"102052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-3087","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Silberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Tackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-6323","authenticated-orcid":false,"given":"Martin","family":"Smoragiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2024.02.003_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2024.02.003_bib0002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2021.05.078","article-title":"Initial findings from a high genetic risk prostate cancer clinic","volume":"156","author":"Sessine","year":"2021","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.clgc.2024.02.003_bib0003","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms22073753","article-title":"Hereditary prostate cancer: genes related, target therapy and prevention","volume":"22","author":"Vietri","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","article-title":"When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials","volume":"3","author":"Antonarakis","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.02.003_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2024.02.003_bib0007","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2024.02.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"9","key":"10.1016\/j.clgc.2024.02.003_bib0009","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10398","key":"10.1016\/j.clgc.2024.02.003_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"38","key":"10.1016\/j.clgc.2024.02.003_bib0011","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/EDBK_205441","article-title":"Practical methods for integrating genetic testing into clinical practice for advanced prostate cancer","author":"Cheng","year":"2018","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"9","key":"10.1016\/j.clgc.2024.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.02.003_bib0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.02.003_bib0014","unstructured":"National Comprehensive Cancer Network (NCCN). Prostate Cancer. Clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed January 20, 2024."},{"key":"10.1016\/j.clgc.2024.02.003_bib0015","unstructured":"National Comprehensive Cancer Network (NCCN). Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Accessed January 20, 2024."},{"issue":"January","key":"10.1016\/j.clgc.2024.02.003_bib0016","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","author":"Tuffaha","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0017","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JU.0000000000003186","article-title":"Clinical impact of a rapid genetic testing model for advanced prostate cancer patients","volume":"209","author":"Breen","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.02.003_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-10429-2","article-title":"Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study","volume":"22","author":"Vlaming","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2024.02.003_bib0019","series-title":"Hereditary Cancer Testing Eligibility Criteria","article-title":"Cancer Care Ontario","year":"2022"},{"issue":"2","key":"10.1016\/j.clgc.2024.02.003_bib0020","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1200\/OP.20.00399","article-title":"Evaluation of a mainstream model of genetic testing for men with prostate cancer","volume":"17","author":"Scheinberg","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0021","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.clgc.2024.02.003_bib0022","unstructured":"FoundationOne\u00aeCDx technical specifications. https:\/\/www.foundationmedicine.qarad.eifu.online\/foundationmedicine\/en\/foundationmedicine. 2019. Accessed January 20, 2024."},{"key":"10.1016\/j.clgc.2024.02.003_bib0023","unstructured":"Resolution ctDx FIRST. https:\/\/www.resolutionbio.com\/assays\/Resolution-ctDx-FIRST.html 2022 Accessed January 20, 2024."},{"key":"10.1016\/j.clgc.2024.02.003_bib0024","unstructured":"Invitae multi-cancer panel. https:\/\/www.invitae.com\/us\/providers\/test-catalog\/test-01101. Accessed January 20, 2024."},{"issue":"2","key":"10.1016\/j.clgc.2024.02.003_bib0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.euf.2019.05.009","article-title":"Screening, active surveillance, and treatment of localized prostate cancer among carriers of germline BRCA mutations","volume":"6","author":"Halstuch","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0026","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1200\/OP.22.00638","article-title":"Implementation of a telehealth genetic testing station to deliver germline testing for men with prostate cancer","volume":"19","author":"Kwon","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.clgc.2024.02.003_bib0027","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","article-title":"Germline and somatic mutations in prostate cancer for the clinician","volume":"17","author":"Cheng","year":"2019","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.clgc.2024.02.003_bib0028","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA Repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.02.003_bib0029","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ijc.32176","article-title":"Germline variation in BRCA1\/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients","volume":"145","author":"Bhaskaran","year":"2019","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2024.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/jnci\/djaa167","article-title":"Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer","volume":"113","author":"Yadav","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.clgc.2024.02.003_bib0031","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.02.003_bib0032","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.clgc.2024.02.003_bib0033","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41379-020-00731-4","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T03:59:30Z","timestamp":1717646370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000247"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102052"}}